News Releases
Eli Lilly Announces Phase 3 Trial Results of Arthritis Drug
INDIANAPOLIS, Feb. 23, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the investigational medicine baricitinib demonstrated a statistically significant improvement compared to placebo in a second consecutive Phase 3 trial in rheumatoid arthritis (RA).
Psoriatic Arthritis Rx Performed Well in Phase 2 Trial
Amgen (NASDAQ:AMGN) and AstraZeneca today announced that results from a Phase 2 study evaluating brodalumab in 168 patients with psoriatic arthritis were published in The New England Journal of Medicine (NEJM).
Teva and Active Biotech Report Positive Results from Phase IIa Study of Laquinimod in Active Lupus Nephritis
Teva Pharmaceutical Industries Ltd. and Active Biotech announced today the results of a Phase IIa study of oral laquinimod designed to assess safety, tolerability and clinical efficacy in patients with active lupus nephritis, one of the most serious manifestations of systemic lupus erythematosus (SLE or lupus) that can lead to chronic kidney failure.
Novartis Rx Ilaris Approved by FDA
Novartis announced today that the US Food and Drug Administration (FDA) has approved Ilaris ® (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older.
Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab
Eli Lilly and Company announced today that it will discontinue the Phase 3 rheumatoid arthritis (RA) program for tabalumab, an anti-BAFF (B cell activating factor) monoclonal antibody, due to lack of efficacy.
New Phase 3 Findings For Psoriatic Arthritis Drug Stelara
Janssen Research & Development, LLC (Janssen) announced today new findings from PSUMMIT II, a Phase 3 investigational study.
Humira Approved in Europe for Treatment of Spondyloarthritis
Abbott announced that the European Commission (EC) has approved Humira (adalimumab) for the treatment of adults with severe axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage.
Rheumatoid Arthritis Drug Shows Positive Results
Roche announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy of the subcutaneous (SC) formulation of RoACTEMRA ( tocilizumab , known as ACTEMRA outside Europe) 162 mg weekly compared to 8 mg/kg RoACTEMRA intravenous (IV) formulation every 4 weeks.
A Plan to Help the Pre-existing Condition Crowd
The U.S. Department of Health and Human Services (HHS) is increasing awareness about a health plan for uninsured Americans with pre-existing conditions created by the Affordable Care Act.